The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer

Background In the last years, several efforts have been made to classify colorectal cancer (CRC) into well-defined molecular subgroups, representing the intrinsic inter-patient heterogeneity, known as Consensus Molecular Subtypes (CMSs). Methods In this work, we performed a meta-analysis of CRC pati...

Full description

Saved in:
Bibliographic Details
Published inJournal of experimental & clinical cancer research Vol. 41; no. 1; pp. 113 - 18
Main Authors Mazzeschi, Martina, Sgarzi, Michela, Romaniello, Donatella, Gelfo, Valerio, Cavallo, Carola, Ambrosi, Francesca, Morselli, Alessandra, Miano, Carmen, Laprovitera, Noemi, Girone, Cinzia, Ferracin, Manuela, Santi, Spartaco, Rihawi, Karim, Ardizzoni, Andrea, Fiorentino, Michelangelo, D’Uva, Gabriele, Győrffy, Balázs, Palmer, Ruth, Lauriola, Mattia
Format Journal Article
LanguageEnglish
Published London BioMed Central 29.03.2022
BioMed Central Ltd
BMC
Subjects
activation
AKT
ALK
ALKAL2
anaplastic lymphoma kinase
Anaplastic Lymphoma Kinase - genetics
Animals
Apoptosis
Biomedical and Life Sciences
Biomedicine
Cancer and Oncology
Cancer och onkologi
Cancer Research
Cancer therapies
CMS1
Colon cancer
Colon Cancer therapy
Colonic Neoplasms - genetics
Colorectal cancer
Cytokines - genetics
Experiments
Gene amplification
Humans
Hydrogels
Immunology
Kinases
Lasers
Ligands
lung-cancer
Medical prognosis
Mice
Microscopy
Neoplasm Recurrence, Local
Non-Hodgkin's lymphomas
Oncology
Patients
Phosphorylation
Polymerization
poor-prognosis
Signalling
Software
Spheroids
tyrosine kinase
United States > US
ALK
3D
Colon Cancer therapy
CMS1
ALKAL2
AKT
Signalling
Online AccessGet full text
ISSN1756-9966
0392-9078
1756-9966
DOI10.1186/s13046-022-02309-1

Cover

Abstract Background In the last years, several efforts have been made to classify colorectal cancer (CRC) into well-defined molecular subgroups, representing the intrinsic inter-patient heterogeneity, known as Consensus Molecular Subtypes (CMSs). Methods In this work, we performed a meta-analysis of CRC patients stratified into four CMSs. We identified a negative correlation between a high level of anaplastic lymphoma kinase (ALK) expression and relapse-free survival, exclusively in CMS1 subtype. Stemming from this observation, we tested cell lines, patient-derived organoids and mice with potent ALK inhibitors, already approved for clinical use. Results ALK interception strongly inhibits cell proliferation already at nanomolar doses, specifically in CMS1 cell lines, while no effect was found in CMS2/3/4 groups. Furthermore, in vivo imaging identified a role for ALK in the dynamic formation of 3D tumor spheroids. Consistently, ALK appeares constitutively phosphorylated in CMS1, and it signals mainly through the AKT axis. Mechanistically, we found that CMS1 cells display several copies of ALKAL2 ligand and ALK-mRNAs, suggesting an autocrine loop mediated by ALKAL2 in the activation of ALK pathway, responsible for the invasive phenotype. Consequently, disruption of ALK axis mediates the pro-apoptotic action of CMS1 cell lines, both in 2D and 3D and enhanced cell-cell adhesion and e-cadherin organization. In agreement with all these findings, the ALK signature encompassing 65 genes statistically associated with worse relapse-free survival in CMS1 subtype. Finally, as a proof of concept, the efficacy of ALK inhibition was demonstrated in both patient-derived organoids and in tumor xenografts in vivo. Conclusions Collectively, these findings suggest that ALK targeting may represent an attractive therapy for CRC, and CMS classification may provide a useful tool to identify patients who could benefit from this treatment. These findings offer rationale and pharmacological strategies for the treatment of CMS1 CRC.
AbstractList Background In the last years, several efforts have been made to classify colorectal cancer (CRC) into well-defined molecular subgroups, representing the intrinsic inter-patient heterogeneity, known as Consensus Molecular Subtypes (CMSs). Methods In this work, we performed a meta-analysis of CRC patients stratified into four CMSs. We identified a negative correlation between a high level of anaplastic lymphoma kinase (ALK) expression and relapse-free survival, exclusively in CMS1 subtype. Stemming from this observation, we tested cell lines, patient-derived organoids and mice with potent ALK inhibitors, already approved for clinical use. Results ALK interception strongly inhibits cell proliferation already at nanomolar doses, specifically in CMS1 cell lines, while no effect was found in CMS2/3/4 groups. Furthermore, in vivo imaging identified a role for ALK in the dynamic formation of 3D tumor spheroids. Consistently, ALK appeares constitutively phosphorylated in CMS1, and it signals mainly through the AKT axis. Mechanistically, we found that CMS1 cells display several copies of ALKAL2 ligand and ALK-mRNAs, suggesting an autocrine loop mediated by ALKAL2 in the activation of ALK pathway, responsible for the invasive phenotype. Consequently, disruption of ALK axis mediates the pro-apoptotic action of CMS1 cell lines, both in 2D and 3D and enhanced cell-cell adhesion and e-cadherin organization. In agreement with all these findings, the ALK signature encompassing 65 genes statistically associated with worse relapse-free survival in CMS1 subtype. Finally, as a proof of concept, the efficacy of ALK inhibition was demonstrated in both patient-derived organoids and in tumor xenografts in vivo. Conclusions Collectively, these findings suggest that ALK targeting may represent an attractive therapy for CRC, and CMS classification may provide a useful tool to identify patients who could benefit from this treatment. These findings offer rationale and pharmacological strategies for the treatment of CMS1 CRC.
Abstract Background In the last years, several efforts have been made to classify colorectal cancer (CRC) into well-defined molecular subgroups, representing the intrinsic inter-patient heterogeneity, known as Consensus Molecular Subtypes (CMSs). Methods In this work, we performed a meta-analysis of CRC patients stratified into four CMSs. We identified a negative correlation between a high level of anaplastic lymphoma kinase (ALK) expression and relapse-free survival, exclusively in CMS1 subtype. Stemming from this observation, we tested cell lines, patient-derived organoids and mice with potent ALK inhibitors, already approved for clinical use. Results ALK interception strongly inhibits cell proliferation already at nanomolar doses, specifically in CMS1 cell lines, while no effect was found in CMS2/3/4 groups. Furthermore, in vivo imaging identified a role for ALK in the dynamic formation of 3D tumor spheroids. Consistently, ALK appeares constitutively phosphorylated in CMS1, and it signals mainly through the AKT axis. Mechanistically, we found that CMS1 cells display several copies of ALKAL2 ligand and ALK-mRNAs, suggesting an autocrine loop mediated by ALKAL2 in the activation of ALK pathway, responsible for the invasive phenotype. Consequently, disruption of ALK axis mediates the pro-apoptotic action of CMS1 cell lines, both in 2D and 3D and enhanced cell-cell adhesion and e-cadherin organization. In agreement with all these findings, the ALK signature encompassing 65 genes statistically associated with worse relapse-free survival in CMS1 subtype. Finally, as a proof of concept, the efficacy of ALK inhibition was demonstrated in both patient-derived organoids and in tumor xenografts in vivo. Conclusions Collectively, these findings suggest that ALK targeting may represent an attractive therapy for CRC, and CMS classification may provide a useful tool to identify patients who could benefit from this treatment. These findings offer rationale and pharmacological strategies for the treatment of CMS1 CRC.
In the last years, several efforts have been made to classify colorectal cancer (CRC) into well-defined molecular subgroups, representing the intrinsic inter-patient heterogeneity, known as Consensus Molecular Subtypes (CMSs). In this work, we performed a meta-analysis of CRC patients stratified into four CMSs. We identified a negative correlation between a high level of anaplastic lymphoma kinase (ALK) expression and relapse-free survival, exclusively in CMS1 subtype. Stemming from this observation, we tested cell lines, patient-derived organoids and mice with potent ALK inhibitors, already approved for clinical use. ALK interception strongly inhibits cell proliferation already at nanomolar doses, specifically in CMS1 cell lines, while no effect was found in CMS2/3/4 groups. Furthermore, in vivo imaging identified a role for ALK in the dynamic formation of 3D tumor spheroids. Consistently, ALK appeares constitutively phosphorylated in CMS1, and it signals mainly through the AKT axis. Mechanistically, we found that CMS1 cells display several copies of ALKAL2 ligand and ALK-mRNAs, suggesting an autocrine loop mediated by ALKAL2 in the activation of ALK pathway, responsible for the invasive phenotype. Consequently, disruption of ALK axis mediates the pro-apoptotic action of CMS1 cell lines, both in 2D and 3D and enhanced cell-cell adhesion and e-cadherin organization. In agreement with all these findings, the ALK signature encompassing 65 genes statistically associated with worse relapse-free survival in CMS1 subtype. Finally, as a proof of concept, the efficacy of ALK inhibition was demonstrated in both patient-derived organoids and in tumor xenografts in vivo. Collectively, these findings suggest that ALK targeting may represent an attractive therapy for CRC, and CMS classification may provide a useful tool to identify patients who could benefit from this treatment. These findings offer rationale and pharmacological strategies for the treatment of CMS1 CRC.
In the last years, several efforts have been made to classify colorectal cancer (CRC) into well-defined molecular subgroups, representing the intrinsic inter-patient heterogeneity, known as Consensus Molecular Subtypes (CMSs). In this work, we performed a meta-analysis of CRC patients stratified into four CMSs. We identified a negative correlation between a high level of anaplastic lymphoma kinase (ALK) expression and relapse-free survival, exclusively in CMS1 subtype. Stemming from this observation, we tested cell lines, patient-derived organoids and mice with potent ALK inhibitors, already approved for clinical use. ALK interception strongly inhibits cell proliferation already at nanomolar doses, specifically in CMS1 cell lines, while no effect was found in CMS2/3/4 groups. Furthermore, in vivo imaging identified a role for ALK in the dynamic formation of 3D tumor spheroids. Consistently, ALK appeares constitutively phosphorylated in CMS1, and it signals mainly through the AKT axis. Mechanistically, we found that CMS1 cells display several copies of ALKAL2 ligand and ALK-mRNAs, suggesting an autocrine loop mediated by ALKAL2 in the activation of ALK pathway, responsible for the invasive phenotype. Consequently, disruption of ALK axis mediates the pro-apoptotic action of CMS1 cell lines, both in 2D and 3D and enhanced cell-cell adhesion and e-cadherin organization. In agreement with all these findings, the ALK signature encompassing 65 genes statistically associated with worse relapse-free survival in CMS1 subtype. Finally, as a proof of concept, the efficacy of ALK inhibition was demonstrated in both patient-derived organoids and in tumor xenografts in vivo. Collectively, these findings suggest that ALK targeting may represent an attractive therapy for CRC, and CMS classification may provide a useful tool to identify patients who could benefit from this treatment. These findings offer rationale and pharmacological strategies for the treatment of CMS1 CRC.
Background In the last years, several efforts have been made to classify colorectal cancer (CRC) into well-defined molecular subgroups, representing the intrinsic inter-patient heterogeneity, known as Consensus Molecular Subtypes (CMSs). Methods In this work, we performed a meta-analysis of CRC patients stratified into four CMSs. We identified a negative correlation between a high level of anaplastic lymphoma kinase (ALK) expression and relapse-free survival, exclusively in CMS1 subtype. Stemming from this observation, we tested cell lines, patient-derived organoids and mice with potent ALK inhibitors, already approved for clinical use. Results ALK interception strongly inhibits cell proliferation already at nanomolar doses, specifically in CMS1 cell lines, while no effect was found in CMS2/3/4 groups. Furthermore, in vivo imaging identified a role for ALK in the dynamic formation of 3D tumor spheroids. Consistently, ALK appeares constitutively phosphorylated in CMS1, and it signals mainly through the AKT axis. Mechanistically, we found that CMS1 cells display several copies of ALKAL2 ligand and ALK-mRNAs, suggesting an autocrine loop mediated by ALKAL2 in the activation of ALK pathway, responsible for the invasive phenotype. Consequently, disruption of ALK axis mediates the pro-apoptotic action of CMS1 cell lines, both in 2D and 3D and enhanced cell-cell adhesion and e-cadherin organization. In agreement with all these findings, the ALK signature encompassing 65 genes statistically associated with worse relapse-free survival in CMS1 subtype. Finally, as a proof of concept, the efficacy of ALK inhibition was demonstrated in both patient-derived organoids and in tumor xenografts in vivo. Conclusions Collectively, these findings suggest that ALK targeting may represent an attractive therapy for CRC, and CMS classification may provide a useful tool to identify patients who could benefit from this treatment. These findings offer rationale and pharmacological strategies for the treatment of CMS1 CRC. Keywords: ALK, ALKAL2, CMS1, Colon Cancer therapy, Signalling, AKT, 3D
In the last years, several efforts have been made to classify colorectal cancer (CRC) into well-defined molecular subgroups, representing the intrinsic inter-patient heterogeneity, known as Consensus Molecular Subtypes (CMSs).BACKGROUNDIn the last years, several efforts have been made to classify colorectal cancer (CRC) into well-defined molecular subgroups, representing the intrinsic inter-patient heterogeneity, known as Consensus Molecular Subtypes (CMSs).In this work, we performed a meta-analysis of CRC patients stratified into four CMSs. We identified a negative correlation between a high level of anaplastic lymphoma kinase (ALK) expression and relapse-free survival, exclusively in CMS1 subtype. Stemming from this observation, we tested cell lines, patient-derived organoids and mice with potent ALK inhibitors, already approved for clinical use.METHODSIn this work, we performed a meta-analysis of CRC patients stratified into four CMSs. We identified a negative correlation between a high level of anaplastic lymphoma kinase (ALK) expression and relapse-free survival, exclusively in CMS1 subtype. Stemming from this observation, we tested cell lines, patient-derived organoids and mice with potent ALK inhibitors, already approved for clinical use.ALK interception strongly inhibits cell proliferation already at nanomolar doses, specifically in CMS1 cell lines, while no effect was found in CMS2/3/4 groups. Furthermore, in vivo imaging identified a role for ALK in the dynamic formation of 3D tumor spheroids. Consistently, ALK appeares constitutively phosphorylated in CMS1, and it signals mainly through the AKT axis. Mechanistically, we found that CMS1 cells display several copies of ALKAL2 ligand and ALK-mRNAs, suggesting an autocrine loop mediated by ALKAL2 in the activation of ALK pathway, responsible for the invasive phenotype. Consequently, disruption of ALK axis mediates the pro-apoptotic action of CMS1 cell lines, both in 2D and 3D and enhanced cell-cell adhesion and e-cadherin organization. In agreement with all these findings, the ALK signature encompassing 65 genes statistically associated with worse relapse-free survival in CMS1 subtype. Finally, as a proof of concept, the efficacy of ALK inhibition was demonstrated in both patient-derived organoids and in tumor xenografts in vivo.RESULTSALK interception strongly inhibits cell proliferation already at nanomolar doses, specifically in CMS1 cell lines, while no effect was found in CMS2/3/4 groups. Furthermore, in vivo imaging identified a role for ALK in the dynamic formation of 3D tumor spheroids. Consistently, ALK appeares constitutively phosphorylated in CMS1, and it signals mainly through the AKT axis. Mechanistically, we found that CMS1 cells display several copies of ALKAL2 ligand and ALK-mRNAs, suggesting an autocrine loop mediated by ALKAL2 in the activation of ALK pathway, responsible for the invasive phenotype. Consequently, disruption of ALK axis mediates the pro-apoptotic action of CMS1 cell lines, both in 2D and 3D and enhanced cell-cell adhesion and e-cadherin organization. In agreement with all these findings, the ALK signature encompassing 65 genes statistically associated with worse relapse-free survival in CMS1 subtype. Finally, as a proof of concept, the efficacy of ALK inhibition was demonstrated in both patient-derived organoids and in tumor xenografts in vivo.Collectively, these findings suggest that ALK targeting may represent an attractive therapy for CRC, and CMS classification may provide a useful tool to identify patients who could benefit from this treatment. These findings offer rationale and pharmacological strategies for the treatment of CMS1 CRC.CONCLUSIONSCollectively, these findings suggest that ALK targeting may represent an attractive therapy for CRC, and CMS classification may provide a useful tool to identify patients who could benefit from this treatment. These findings offer rationale and pharmacological strategies for the treatment of CMS1 CRC.
Background In the last years, several efforts have been made to classify colorectal cancer (CRC) into well-defined molecular subgroups, representing the intrinsic inter-patient heterogeneity, known as Consensus Molecular Subtypes (CMSs). Methods In this work, we performed a meta-analysis of CRC patients stratified into four CMSs. We identified a negative correlation between a high level of anaplastic lymphoma kinase (ALK) expression and relapse-free survival, exclusively in CMS1 subtype. Stemming from this observation, we tested cell lines, patient-derived organoids and mice with potent ALK inhibitors, already approved for clinical use. Results ALK interception strongly inhibits cell proliferation already at nanomolar doses, specifically in CMS1 cell lines, while no effect was found in CMS2/3/4 groups. Furthermore, in vivo imaging identified a role for ALK in the dynamic formation of 3D tumor spheroids. Consistently, ALK appeares constitutively phosphorylated in CMS1, and it signals mainly through the AKT axis. Mechanistically, we found that CMS1 cells display several copies of ALKAL2 ligand and ALK-mRNAs, suggesting an autocrine loop mediated by ALKAL2 in the activation of ALK pathway, responsible for the invasive phenotype. Consequently, disruption of ALK axis mediates the pro-apoptotic action of CMS1 cell lines, both in 2D and 3D and enhanced cell-cell adhesion and e-cadherin organization. In agreement with all these findings, the ALK signature encompassing 65 genes statistically associated with worse relapse-free survival in CMS1 subtype. Finally, as a proof of concept, the efficacy of ALK inhibition was demonstrated in both patient-derived organoids and in tumor xenografts in vivo. Conclusions Collectively, these findings suggest that ALK targeting may represent an attractive therapy for CRC, and CMS classification may provide a useful tool to identify patients who could benefit from this treatment. These findings offer rationale and pharmacological strategies for the treatment of CMS1 CRC.
ArticleNumber 113
Audience Academic
Author Cavallo, Carola
Győrffy, Balázs
Santi, Spartaco
D’Uva, Gabriele
Ambrosi, Francesca
Mazzeschi, Martina
Ferracin, Manuela
Sgarzi, Michela
Lauriola, Mattia
Morselli, Alessandra
Girone, Cinzia
Gelfo, Valerio
Palmer, Ruth
Laprovitera, Noemi
Rihawi, Karim
Ardizzoni, Andrea
Romaniello, Donatella
Miano, Carmen
Fiorentino, Michelangelo
Author_xml – sequence: 1
  givenname: Martina
  surname: Mazzeschi
  fullname: Mazzeschi, Martina
  organization: Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna
– sequence: 2
  givenname: Michela
  surname: Sgarzi
  fullname: Sgarzi, Michela
  organization: Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna
– sequence: 3
  givenname: Donatella
  surname: Romaniello
  fullname: Romaniello, Donatella
  organization: Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna
– sequence: 4
  givenname: Valerio
  surname: Gelfo
  fullname: Gelfo, Valerio
  organization: Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna
– sequence: 5
  givenname: Carola
  surname: Cavallo
  fullname: Cavallo, Carola
  organization: Laboratory of Preclinical Studies for Regenerative Medicine of the Musculoskeletal System (RAMSES), (IRCCS) Istituto Ortopedico Rizzoli
– sequence: 6
  givenname: Francesca
  surname: Ambrosi
  fullname: Ambrosi, Francesca
  organization: Pathology Unit, Maggiore Hospital, AUSL Bologna
– sequence: 7
  givenname: Alessandra
  surname: Morselli
  fullname: Morselli, Alessandra
  organization: Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna
– sequence: 8
  givenname: Carmen
  surname: Miano
  fullname: Miano, Carmen
  organization: National Laboratory of Molecular Biology and Stem Cell Engineering, National Institute of Biostructures and Biosystems (INBB)
– sequence: 9
  givenname: Noemi
  surname: Laprovitera
  fullname: Laprovitera, Noemi
  organization: Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna
– sequence: 10
  givenname: Cinzia
  surname: Girone
  fullname: Girone, Cinzia
  organization: Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna
– sequence: 11
  givenname: Manuela
  surname: Ferracin
  fullname: Ferracin, Manuela
  organization: Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna
– sequence: 12
  givenname: Spartaco
  surname: Santi
  fullname: Santi, Spartaco
  organization: Institute of Molecular Genetics, National Research Council of Italy, IRCCS-Institute Orthopaedic Rizzoli
– sequence: 13
  givenname: Karim
  surname: Rihawi
  fullname: Rihawi, Karim
  organization: Medical Oncology, IRCSS Azienda-Ospedaliero Universitaria di Bologna
– sequence: 14
  givenname: Andrea
  surname: Ardizzoni
  fullname: Ardizzoni, Andrea
  organization: Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Medical Oncology, IRCSS Azienda-Ospedaliero Universitaria di Bologna
– sequence: 15
  givenname: Michelangelo
  surname: Fiorentino
  fullname: Fiorentino, Michelangelo
  organization: Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna
– sequence: 16
  givenname: Gabriele
  surname: D’Uva
  fullname: D’Uva, Gabriele
  organization: Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, National Laboratory of Molecular Biology and Stem Cell Engineering, National Institute of Biostructures and Biosystems (INBB)
– sequence: 17
  givenname: Balázs
  surname: Győrffy
  fullname: Győrffy, Balázs
  organization: Semmelweis University Department of Bioinformatics and 2nd Department Of Pediatrics, TTK Cancer Biomarker Research Group, Institute of Enzymology
– sequence: 18
  givenname: Ruth
  surname: Palmer
  fullname: Palmer, Ruth
  organization: Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg
– sequence: 19
  givenname: Mattia
  surname: Lauriola
  fullname: Lauriola, Mattia
  email: mattia.lauriola2@unibo.it
  organization: Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Centre for Applied Biomedical Research (CRBA), Bologna University Hospital Authority St. Orsola -Malpighi Polyclinic
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35351152$$D View this record in MEDLINE/PubMed
https://gup.ub.gu.se/publication/315281$$DView record from Swedish Publication Index
BookMark eNp9kl2L3CAUhkPZ0v1o_0AvilAovck2mmjiTWFY-rF0oDfbazF6zDg4OtVky_bX1-zMtjNLWYIkHp_3jb6e8-LEBw9F8RpXlxh37EPCddWwsiIkj7riJX5WnOGWspJzxk4Ovk-L85TWVcUwx_xFcVrTmmJMyVnx-2YFSE5jUNF6QC6ELQoGLZbfUAQF2zFEJL2eC4slQc4O88ymXERSjTZ42TtAo4wDjMh6pIJP4NOU0CY4UJOTEaWpH--2gHBedSEz0iuIL4vnRroEr_bvi-LH5083V1_L5fcv11eLZalYy8ayNYZV0LZKE00oZb0GjSsmaQPGUF5Rzig1DcWm7cA0hkigval6TBvaYOjri-J656uDXItttBsZ70SQVtwXQhyEjKNVDoTGVPetwsrgrtFa8o7WVSeJbJjmPW-zV7nzSr9gO_VHbsO0Fbk0TCKBqHO6Hc78xx2f4Q1oBX6M0h3Jjle8XYkh3IqOM4Jbng3e7w1i-DlBGsXGJgXOSQ9hSoKwfMoWs3be29tH6DpM0edoM0Ux70h9SA0yH9h6E_J_1WwqFoxz2nQdJZm6_A-VHw0bm68YjM31I8G7A8EKpBtXKbhp7pB0DL45TORvFA8tmYFuB6gYUopghLKjnH3yFqwTuBJz94td94vc_eK--8WcNnkkfXB_UlTvrzTDfoD4L7YnVH8AINcVeQ
CitedBy_id crossref_primary_10_3390_biom13101490
crossref_primary_10_1016_j_isci_2023_108367
crossref_primary_10_15252_embr_202356937
crossref_primary_10_1016_j_biopha_2022_114162
crossref_primary_10_1016_j_prp_2024_155450
crossref_primary_10_1186_s13148_022_01361_0
crossref_primary_10_3390_cancers15102746
crossref_primary_10_1186_s13046_023_02857_0
Cites_doi 10.1016/j.bbrc.2015.02.114
10.1158/1078-0432.CCR-20-4073
10.1016/j.celrep.2021.109363
10.1186/s12943-017-0691-y
10.18632/oncotarget.12354
10.3390/cancers10030064
10.1038/nm.3175
10.1038/onc.2010.595
10.1016/j.cell.2010.06.011
10.1371/journal.pmed.1001453
10.1016/j.phrs.2012.11.007
10.1158/2159-8290.CD-11-0109
10.3389/fonc.2018.00447
10.1073/pnas.1520099112
10.1038/nature14969
10.1038/sj.onc.1205735
10.1101/mcs.a001115
10.1038/s41563-019-0338-z
10.1038/s41592-019-0501-0
10.5858/arpa.2017-0388-CP
10.1038/bjc.2013.641
10.1111/apm.12940
10.1038/nrc2291
10.1074/jbc.M501972200
10.1038/nm.3967
10.1038/nrc3580
10.1038/nm.3174
10.1186/1471-2407-12-260
10.1158/2159-8290.CD-12-0009
10.3390/cancers10100355
10.1038/ncomms8002
10.1038/s41598-019-47000-2
10.1158/1541-7786.MCR-08-0522
10.1038/nrm2236
10.1186/s12943-018-0776-2
10.1158/1078-0432.CCR-08-2762
10.15252/embj.2020105784
10.1371/journal.pone.0092147
10.1186/s12943-017-0609-8
10.1016/j.modgep.2005.11.006
10.1038/srep37169
10.7150/jca.46447
10.7554/eLife.09811
10.1038/nrclinonc.2009.237
10.1200/JCO.2011.37.8588
10.1093/annonc/mdw301
10.1038/nm.2673
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ADTPV
AOWAS
F1U
DOA
DOI 10.1186/s13046-022-02309-1
DatabaseName Springer Nature Open Access Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
SwePub
SwePub Articles
SWEPUB Göteborgs universitet
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList


MEDLINE

MEDLINE - Academic

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-9966
EndPage 18
ExternalDocumentID oai_doaj_org_article_d15db7c1cf184dda985308a2a46d9b97
oai_gup_ub_gu_se_315281
PMC8962179
A699548852
35351152
10_1186_s13046_022_02309_1
Genre Meta-Analysis
Journal Article
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GrantInformation_xml – fundername: Associazione Italiana per la Ricerca sul Cancro
  grantid: AIRC fellowship for Italy
  funderid: http://dx.doi.org/10.13039/501100005010
– fundername: Ministero dell’Istruzione, dell’Università e della Ricerca
  grantid: 2017TATYMP_002
  funderid: http://dx.doi.org/10.13039/501100003407
– fundername: Regione Emilia-Romagna
  grantid: Bando Regionale “Alte Competenze per la Ricerca e il Trasferimento Tecnologico” 2018
  funderid: http://dx.doi.org/10.13039/501100009879
– fundername: Fondazione Cariplo
  grantid: Cariplo 2017-0800
  funderid: http://dx.doi.org/10.13039/501100002803
– fundername: Università di Bologna
  grantid: eDIMES Lab funds
  funderid: http://dx.doi.org/10.13039/501100005969
– fundername: Fondazione Cariplo
  grantid: Cariplo 2017-0800
– fundername: Regione Emilia-Romagna
  grantid: Bando Regionale "Alte Competenze per la Ricerca e il Trasferimento Tecnologico" 2018
– fundername: Università di Bologna
  grantid: eDIMES Lab funds
– fundername: Associazione Italiana per la Ricerca sul Cancro
  grantid: AIRC fellowship for Italy
– fundername: Ministero dell'Istruzione, dell'Università e della Ricerca
  grantid: 2017TATYMP_002
– fundername: ;
  grantid: Bando Regionale “Alte Competenze per la Ricerca e il Trasferimento Tecnologico” 2018
– fundername: ;
  grantid: eDIMES Lab funds
– fundername: ;
  grantid: 2017TATYMP_002
– fundername: ;
  grantid: Cariplo 2017-0800
– fundername: ;
  grantid: AIRC fellowship for Italy
GroupedDBID ---
0R~
29K
2WC
4.4
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
ABDBF
ABUWG
ACGFO
ACGFS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
D-I
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TR2
TUS
UKHRP
~8M
AAYXX
ALIPV
CITATION
-5E
-5G
-A0
-BR
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
2VQ
53G
ADTPV
AHSBF
AOWAS
EJD
F1U
H13
IPNFZ
P6G
RIG
UDS
ID FETCH-LOGICAL-c676t-7ff60e77cd2d2556bded106a54eff59059655f451f78ef4f2ae5bf0b154541eb3
IEDL.DBID M48
ISSN 1756-9966
0392-9078
IngestDate Wed Aug 27 01:25:27 EDT 2025
Tue Sep 09 23:54:26 EDT 2025
Thu Aug 21 18:06:20 EDT 2025
Thu Sep 04 20:02:22 EDT 2025
Fri Jul 25 02:25:22 EDT 2025
Tue Jun 17 21:45:48 EDT 2025
Tue Jun 10 20:14:51 EDT 2025
Thu May 22 21:21:38 EDT 2025
Thu Jan 02 22:54:31 EST 2025
Thu Apr 24 23:10:05 EDT 2025
Tue Jul 01 02:26:47 EDT 2025
Sat Sep 06 07:24:03 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords ALK
3D
Colon Cancer therapy
CMS1
ALKAL2
AKT
Signalling
Language English
License 2022. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c676t-7ff60e77cd2d2556bded106a54eff59059655f451f78ef4f2ae5bf0b154541eb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s13046-022-02309-1
PMID 35351152
PQID 2651982377
PQPubID 105475
PageCount 18
ParticipantIDs doaj_primary_oai_doaj_org_article_d15db7c1cf184dda985308a2a46d9b97
swepub_primary_oai_gup_ub_gu_se_315281
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8962179
proquest_miscellaneous_2645471677
proquest_journals_2651982377
gale_infotracmisc_A699548852
gale_infotracacademiconefile_A699548852
gale_healthsolutions_A699548852
pubmed_primary_35351152
crossref_citationtrail_10_1186_s13046_022_02309_1
crossref_primary_10_1186_s13046_022_02309_1
springer_journals_10_1186_s13046_022_02309_1
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-03-29
PublicationDateYYYYMMDD 2022-03-29
PublicationDate_xml – month: 03
  year: 2022
  text: 2022-03-29
  day: 29
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Journal of experimental & clinical cancer research
PublicationTitleAbbrev J Exp Clin Cancer Res
PublicationTitleAlternate J Exp Clin Cancer Res
PublicationYear 2022
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References 2309_CR25
P Bavi (2309_CR26) 2013; 109
JC Van Gaal (2309_CR24) 2012; 30
2309_CR29
H Mano (2309_CR9) 2012; 2
V Gelfo (2309_CR31) 2016; 7
E Lin (2309_CR28) 2009; 7
C Moog-Lutz (2309_CR39) 2005; 280
D Hörl (2309_CR43) 2019; 16
E Vernersson (2309_CR16) 2006; 6
C Cremolini (2309_CR33) 2015; 12
2309_CR32
N Hari (2309_CR42) 2019; 9
L Marisa (2309_CR4) 2013; 10
A Bertotti (2309_CR8) 2015; 526
B Perez Villamil (2309_CR2) 2012; 12
2309_CR37
C Lobello (2309_CR48) 2018; 10
A Amatu (2309_CR27) 2015; 113
VR Holla (2309_CR22) 2017; 3
YP Mosse (2309_CR38) 2009; 15
E Medico (2309_CR7) 2015; 6
B Hallberg (2309_CR18) 2016; 27
P Mazot (2309_CR21) 2011; 30
2309_CR40
2309_CR47
2309_CR46
2309_CR45
V Gelfo (2309_CR30) 2018; 10
E Vilar (2309_CR34) 2010; 7
2309_CR49
R Roskoski (2309_CR11) 2013; 68
KCG Berg (2309_CR35) 2017; 16
E De Sousa (2309_CR5) 2013; 19
A Bertotti (2309_CR44) 2011; 1
F Pampaloni (2309_CR36) 2007; 8
B Hallberg (2309_CR10) 2013; 13
2309_CR13
AV Reshetnyak (2309_CR14) 2015; 112
R Chiarle (2309_CR19) 2008; 8
2309_CR12
2309_CR17
2309_CR15
J Guinney (2309_CR6) 2015; 21
G Umapathy (2309_CR20) 2019; 127
I Miyake (2309_CR23) 2002; 21
A Sadanandam (2309_CR1) 2013; 19
F Guo (2309_CR41) 2015; 459
2309_CR3
References_xml – volume: 459
  start-page: 398
  year: 2015
  ident: 2309_CR41
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2015.02.114
– ident: 2309_CR49
  doi: 10.1158/1078-0432.CCR-20-4073
– ident: 2309_CR40
  doi: 10.1016/j.celrep.2021.109363
– volume: 16
  start-page: 116
  year: 2017
  ident: 2309_CR35
  publication-title: Mol Cancer Mol Cancer
  doi: 10.1186/s12943-017-0691-y
– volume: 7
  start-page: 72167
  year: 2016
  ident: 2309_CR31
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.12354
– volume: 10
  start-page: 64
  year: 2018
  ident: 2309_CR48
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers10030064
– volume: 19
  start-page: 619
  year: 2013
  ident: 2309_CR1
  publication-title: Nat Med
  doi: 10.1038/nm.3175
– volume: 30
  start-page: 2017
  year: 2011
  ident: 2309_CR21
  publication-title: Oncogene.
  doi: 10.1038/onc.2010.595
– ident: 2309_CR12
  doi: 10.1016/j.cell.2010.06.011
– volume: 10
  start-page: e1001453
  year: 2013
  ident: 2309_CR4
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.1001453
– volume: 68
  start-page: 68
  year: 2013
  ident: 2309_CR11
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2012.11.007
– volume: 1
  start-page: 508
  year: 2011
  ident: 2309_CR44
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-11-0109
– ident: 2309_CR32
  doi: 10.3389/fonc.2018.00447
– volume: 112
  start-page: 15862
  year: 2015
  ident: 2309_CR14
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1520099112
– volume: 526
  start-page: 263
  year: 2015
  ident: 2309_CR8
  publication-title: Nature.
  doi: 10.1038/nature14969
– volume: 113
  start-page: 1730
  year: 2015
  ident: 2309_CR27
  publication-title: Nat Publ Group
– volume: 21
  start-page: 5823
  year: 2002
  ident: 2309_CR23
  publication-title: Oncogene.
  doi: 10.1038/sj.onc.1205735
– volume: 3
  year: 2017
  ident: 2309_CR22
  publication-title: Mol Case Stud
  doi: 10.1101/mcs.a001115
– ident: 2309_CR46
  doi: 10.1038/s41563-019-0338-z
– volume: 16
  start-page: 870
  year: 2019
  ident: 2309_CR43
  publication-title: Nat Methods
  doi: 10.1038/s41592-019-0501-0
– ident: 2309_CR45
  doi: 10.5858/arpa.2017-0388-CP
– volume: 109
  start-page: 2735
  year: 2013
  ident: 2309_CR26
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2013.641
– volume: 127
  start-page: 288
  year: 2019
  ident: 2309_CR20
  publication-title: APMIS.
  doi: 10.1111/apm.12940
– volume: 8
  start-page: 11
  year: 2008
  ident: 2309_CR19
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2291
– volume: 280
  start-page: 26039
  year: 2005
  ident: 2309_CR39
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M501972200
– volume: 21
  start-page: 1350
  year: 2015
  ident: 2309_CR6
  publication-title: Nat Med
  doi: 10.1038/nm.3967
– volume: 13
  start-page: 685
  year: 2013
  ident: 2309_CR10
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3580
– volume: 19
  start-page: 614
  year: 2013
  ident: 2309_CR5
  publication-title: Nat Med
  doi: 10.1038/nm.3174
– volume: 12
  start-page: 260
  year: 2012
  ident: 2309_CR2
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-12-260
– volume: 2
  start-page: 495
  year: 2012
  ident: 2309_CR9
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-12-0009
– volume: 10
  start-page: 355
  year: 2018
  ident: 2309_CR30
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers10100355
– volume: 6
  start-page: 7002
  year: 2015
  ident: 2309_CR7
  publication-title: Nat Commun
  doi: 10.1038/ncomms8002
– volume: 9
  start-page: 10601
  year: 2019
  ident: 2309_CR42
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-47000-2
– volume: 7
  start-page: 1466
  year: 2009
  ident: 2309_CR28
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-08-0522
– volume: 8
  start-page: 839
  year: 2007
  ident: 2309_CR36
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm2236
– volume: 12
  start-page: 607
  year: 2015
  ident: 2309_CR33
  publication-title: Nat Publ Group
– ident: 2309_CR17
  doi: 10.1186/s12943-018-0776-2
– volume: 15
  start-page: 5609
  year: 2009
  ident: 2309_CR38
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-08-2762
– ident: 2309_CR47
  doi: 10.15252/embj.2020105784
– ident: 2309_CR25
  doi: 10.1371/journal.pone.0092147
– ident: 2309_CR37
  doi: 10.1186/s12943-017-0609-8
– volume: 6
  start-page: 448
  year: 2006
  ident: 2309_CR16
  publication-title: Gene Expr Patterns
  doi: 10.1016/j.modgep.2005.11.006
– ident: 2309_CR3
  doi: 10.1038/srep37169
– ident: 2309_CR15
  doi: 10.7150/jca.46447
– ident: 2309_CR13
  doi: 10.7554/eLife.09811
– volume: 7
  start-page: 153
  year: 2010
  ident: 2309_CR34
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2009.237
– volume: 30
  start-page: 308
  year: 2012
  ident: 2309_CR24
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.37.8588
– volume: 27
  start-page: iii4
  year: 2016
  ident: 2309_CR18
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdw301
– ident: 2309_CR29
  doi: 10.1038/nm.2673
SSID ssj0061919
Score 2.370383
SecondaryResourceType review_article
Snippet Background In the last years, several efforts have been made to classify colorectal cancer (CRC) into well-defined molecular subgroups, representing the...
In the last years, several efforts have been made to classify colorectal cancer (CRC) into well-defined molecular subgroups, representing the intrinsic...
Background In the last years, several efforts have been made to classify colorectal cancer (CRC) into well-defined molecular subgroups, representing the...
Abstract Background In the last years, several efforts have been made to classify colorectal cancer (CRC) into well-defined molecular subgroups, representing...
SourceID doaj
swepub
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 113
SubjectTerms activation
AKT
ALK
ALKAL2
anaplastic lymphoma kinase
Anaplastic Lymphoma Kinase - genetics
Animals
Apoptosis
Biomedical and Life Sciences
Biomedicine
Cancer and Oncology
Cancer och onkologi
Cancer Research
Cancer therapies
CMS1
Colon cancer
Colon Cancer therapy
Colonic Neoplasms - genetics
Colorectal cancer
Cytokines - genetics
Experiments
Gene amplification
Humans
Hydrogels
Immunology
Kinases
Lasers
Ligands
lung-cancer
Medical prognosis
Mice
Microscopy
Neoplasm Recurrence, Local
Non-Hodgkin's lymphomas
Oncology
Patients
Phosphorylation
Polymerization
poor-prognosis
Signalling
Software
Spheroids
tyrosine kinase
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2ggJEQHCBqnMSv44KoKmg5Uak3y_FjWWlJVs3mwq9nJi-aIpUL2tPak117PB7PxDPfEPKmcgHfJshU8ijSsnAB9pyMKZeFVsIrb_tah2ffxMl5-eWCX1wp9YUxYQM88MC4I8-4r6RjLoIv4r3VcL5kyua2FF5Xus8jz3Q2OVODDgavgOkpRUaJo5bhBWCKketoc-uULY6hHq3_b5185VC6HjA535peQxjtT6Xje-TuaE7S1TCN--RWqB-Q22fjhflD8gvEgNpu3zjM8qPbptnRJtLV6VcKqi7swOOmtvbYsDrN6Xazxm-bFhrpkPKAqVV0iBenm5o6jL6u266lP6fCurTtKnyTSxlFCGygQUm6fETOjz9__3SSjuUWUiek2KcyRpEFKZ3PPQKTVT54cBgtL0OMXGOdHs5jyVmUKsQy5jbwKmYVGmElA6f8MTmomzo8JZRxW4SsqEoPnxBVpaMQymKaV4xZlAlhE_eNG7HIsSTG1vQ-iRJmWDEDK2b6FTMsIe_nZ3YDEseN1B9xUWdKRNHuG0C2zChb5l-ylZBXKBJmSEmddYFZCUTRU4rnCXnXU6A2gAk4OyY1ABsQV2tBebighF3slt2T2JlRi7QmF2BfI5oQjOT13I1PYmRcHZoOaRCSjQmkeTJI6TzpguM1Mf64XMjvgivLnnrzo8cYV1qAs6oT8mGS9D_Duonrb4fdsPiHdbcz0LTuTBtMAeNR7Nn_WJ7n5E7eb2msRnhIDvaXXXgBJuK-etlrg9-2pGEa
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgkRAXxJvCAkZCcIBo6yR-5IQKYrWCXU6s1Jvl-FEqlaQ0zYVfz4zzWLJIVU-1J61jz4xn7JlvCHlTWo-nCTKRPIgkz6wHmZMh4TIrlHDKmVjr8OK7OLvMvy75sj9wa_qwykEnRkXtaotn5CepAFsDkVXkx-3vBKtG4e1qX0LjJrnFwBLB0g1yOTpc4BvEwh6wQ4oE7fohaUaJk4bhlWCCsexohRcJm2xMEb__fy39zzZ1PYRyvEe9hjka96nTe-Rub2DSRccR98kNXz0gty_6K_SH5A8wBjXtvraY90c3db2ldaCL828UlJ_fgg9OTeWwYXGe0s16hd_WDTTSLgkCk61oF0FO1xW1GI9dNW1Dfw2ldmnTlni2SxlFUGygQd7aPSKXp19-fD5L-gIMiRVS7BMZgph7Ka1LHUKVlc47cCENz30IvMDKPZyHnLMglQ95SI3nZZiXaJblDNz0x-Soqiv_lFDGTebnWZk7-PigyiIIoQwmfoUwD3JG2DD72vbo5FgkY6Ojl6KE7lZMw4rpuGKazcj78Zlth81xkPoTLupIibjasaHerXQvptox7kppmQ3g-TpnCrBm5sqkJheuKAsY5itkCd0lqY7aQS8E4uopxdMZeRcpUD_AC1jTpznANCDS1oTyeEIJcm2n3QPb6V6vNPpKCmbk9diNT2KsXOXrFmkQpI0JpHnScen40hnHi2P8cTnh38msTHuq9c-IOq4KAe5rMSMfBk6_GtahWX_bScPkH1btVkPTqtWN1xmMR7Fnh1_3ObmTRmHFyoPH5Gi_a_0LMAf35cso838BnYFaDQ
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature Open Access Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZQkRAXxJuFAkZCcICIOIkfOS4rqgpaTlTqzfJzu9KSrJrNhV_PTF40BVVCOcUeJ45nxp6JPd8Q8ta6gH8TZCJ5FEmRuwA6J2PCZV4q4ZU3Xa7D0-_i-Kz4es7PB5gcjIW5un_PlPjUMNy6S_DMOVrLZQKezm0OhSjNK7EaZ13wA1g5BsX8s91s4enw-f-eha8sQ9ePSE77pNcwRbt16Og-uTcYkHTZc_wBuRWqh-TO6bBF_oj8AsZT0-5rh3F9dFvXO1pHujz5RmFyCzvwsampPBYsTzK63azxbtNAIe2DHDCYivYnxOmmog7PW1dN29CfYypd2rQW_91SRhH0GmhQdi4fk7OjLz9Wx8mQYCFxQop9ImMUaZDS-cwjFJn1wYOLaHgRYuQlZubhPBacRalCLGJmArcxtWh2FQzc8CfkoKqr8IxQxk0e0twWHq4QlS2jEMpgYFeMaZQLwsbR125AH8ckGFvdeSFK6J5jGjimO45ptiAfpja7HnvjRurPyNSJEnGzuwIQJz2oofaMeysdcxE8W-9NCdZKqkxmCuFLW0I3X6NI6D4IddJ-vRSIm6cUzxbkfUeB-g8f4MwQxgDDgEhaM8rDGSXorZtXj2Knh3mj0ZkAixrxg6Anb6ZqbIln4apQt0iDIGxMIM3TXkqnj845bgzjw-VMfmejMq-pNhcdqrgqBbin5YJ8HCX9T7duGvV3vTbM3rBudxqK1q1ugs6hP4o9_7_nviB3s055MdPgITnYX7bhJZh_e_uq0_vfi2pQ1Q
  priority: 102
  providerName: Springer Nature
Title The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer
URI https://link.springer.com/article/10.1186/s13046-022-02309-1
https://www.ncbi.nlm.nih.gov/pubmed/35351152
https://www.proquest.com/docview/2651982377
https://www.proquest.com/docview/2645471677
https://pubmed.ncbi.nlm.nih.gov/PMC8962179
https://gup.ub.gu.se/publication/315281
https://doaj.org/article/d15db7c1cf184dda985308a2a46d9b97
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELfGJiFeEN8URjESggcI1Gn8kQeE2mrTBNuEJipNvFhJbJdKJSlNIwF_PXfOB2RMe0KVKsU-t459Z9_5fL8j5HmaWTxNkIHkTgTROLMgc9IFXI5jJYwyic91eHIqjubRh3N-vkPadEfNAJaXmnaYT2q-Wb358f3nexD4d17glXhbMnTvBXgvHTXqOABraM_7i_AqX9R5FcBWYHEbOHNpu97m5DH8_12p_9qqLl6j7HypF3BH_V51eIvcbJRMOqm54jbZsfkdcv2kcaPfJb-AOWhSbYsMY__oqijWtHB0cvyRwgJo12CH0yQ3WDA5DulqucCnZQmFtA6EwIArWt8ip8ucZngnOy-rkn5r0-3SskrxfJcyisDYQIP8tblH5ocHn2dHQZOEIciEFNtAOidGVsrMhAbhylJjDZiRCY-sczzG7D2cu4gzJ5V1kQsTy1M3SlE1ixiY6vfJbl7k9iGhjCdjOxqnkYGPdSqNnRAqweAv50ZODghrR19nDUI5JspYaW-pKKHrGdMwY9rPmGYD8qprs67xOa6knuKkdpSIre0Lis1CN6KqDeMmlRnLHFi_xiQxaDQjlYRJJEycxtDNp8gSug5U7VYIPRGIracUDwfkpadAroUXyJIm1AGGAdG2epT7PUqQ7axf3bKdbkVDhwK0bsQYgp4866qxJd6Xy21RIQ0CtTGBNA9qLu1eeszReYw_Lnv82xuVfk2-_OqRx1UswISNB-R1y-l_unXVqL-opaH3D4tqraFoUenS6jH0R7FH_2N6HpMboRdpzFG4T3a3m8o-AcVxmw7JNXkuh2RvenD66QyeZmI29IcwQ79OwPfZ9MtvI6Jt1g
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELbKVgJeEDcLhRqJ44FG3Ry2k4cKbaHVlj2EUCv1zSSxvay0JMtmIwQ_jt_GjHOUFKlv1T6tPUl8jGc89sw3hLxKUo2nCcIRzHAn8FMNa04Yhwk_CrkKVWxzHU5nfHQWfDpn51vkTxMLg26VjUy0glrlKZ6R73sc9hqIrCLer344mDUKb1ebFBpxnVpBHViIsTqwY6x__QQTrjg4-Qjz_drzjo9OP4ycOsuAk3LBN44whg-0EKnyFOJxJUorsJNiFmhjWITpaRgzAXONCLUJjBdrlphBgnuPwAVbFN57g2wH2OUe2T48mn3-0ugCsE5sahHQ0dxBy6IJ2wn5fuHipaSD3vRoB0SO21GNNoPA_3riH0V52Ymzvcm9hHpqNeXxXXKn3uLSYcWT98iWzu6Tm9P6Ev8B-Q2sSeNyk6cYeUiXeb6iuaHDyZiC-NWrTb6mcaawYDjx6HIxx3-LAgppFYaB4V608mGni4ym6BGeFWVBvzfJfmlRJni6TF2KsNxAg9y9fkjOrmVyHpFelmf6CaEui3098JNAwU-bMIkM52GMoWfGDIzoE7cZfZnW-OiYpmMprZ0UclnNmIQZk3bGpNsn79pnVhU6yJXUhzipLSUie9uCfD2XtaCQymUqEambGrC9lYoj2E8NwtiLA66iJIJm7iJLyCpMtpVPcsgR2S8Mmdcnby0FSijoQBrXgRYwDIj11aHc6VCCZEm71Q3byVqyFfJiHfbJy7Yan0RvvUznJdIgTJzLkeZxxaVtp32GV9f4ctHh386odGuyxTeLex5GHAzoqE_2Gk6_aNZVo_6mWg2dL8zLlYSieSkLLX1oT-g-vbq7u-TW6HQ6kZOT2fgZue3ZhYt5EHdIb7Mu9XPYnG6SF7UEoOTrdQudv3fznjs
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELfQJk28IL4pDGYkBA8QrU7ir8fwUY2um5Bg0t6sJLa7SiWpmuaFv567fLEMNAn1qfYlcey781189ztC3mS5w68JMpDciyCOcgcyJ33AZaSVsMqmTa3Ds3NxchHPL_nltSz-Jtq9P5JscxoQpanYHW-sb0VcieOK4YFegJHoaEPrAPyffcW1BvdrP0nm3-e9Ngb_gOk-WeafV442pAa3_2_tfG17uhk6OZyf3sAabfan2X1yrzMsadJywgNyxxUPycFZd3T-iPwChqBpvStzzPej67Lc0NLTZHFKQem5DfjeNC0sNiSLkK5XS_y3qqCRtskPmGRF28hxuipojnHYRVVX9GdfYpdWdYbfdCmjCIYNNMhT28fkYvblx6eToCu8EORCil0gvRdTJ2VuQ4sQZZl1FlzHlMfOe66xYg_nPubMS-V87MPU8cxPMzTHYgbu-ROyV5SFe0Yo42nkplEWW_g5rzLthVApJnx5P_VyQlg_-ybvUMmxOMbaNN6JEqZdMQMrZpoVM2xC3g_XbFpMjlupP-KiDpSIp900lNul6cTTWMZtJnOWe_B4rU01WDFTlYZpLKzONAzzCFnCtMmpg1YwiUA8PaV4OCHvGgrUC_ACedqlN8A0IMLWiPJwRAnynI-7e7YznT6pTCjA0kZcIRjJ66Ebr8QYucKVNdIgOBsTSPO05dLhpSOOB8Z4czni39GsjHuK1VWDNq60ALdVT8iHntP_DOu2WX_bSsPoCct6Y6BpWZvKmQjGo9jz_7vvETn49nlmFl_PT1-Qu2Ejx1iM8JDs7ba1ewkW4i571SmB31FZXYI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+autocrine+loop+of+ALK+receptor+and+ALKAL2+ligand+is+an+actionable+target+in+consensus+molecular+subtype+1+colon+cancer&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Martina+Mazzeschi&rft.au=Michela+Sgarzi&rft.au=Donatella+Romaniello&rft.au=Valerio+Gelfo&rft.date=2022-03-29&rft.pub=BMC&rft.eissn=1756-9966&rft.volume=41&rft.issue=1&rft.spage=1&rft.epage=18&rft_id=info:doi/10.1186%2Fs13046-022-02309-1&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_d15db7c1cf184dda985308a2a46d9b97
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon